{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:29:49Z","timestamp":1785886189646,"version":"3.56.0"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Cendakimab selectively targets interleukin (IL)\u201313, a type 2 cytokine implicated in atopic dermatitis (AD) pathogenesis, by inhibiting binding to its receptors (IL13R-\u03b11 and IL13R-\u03b12). Proof-of-concept work in AD supports using cendakimab for type 2 inflammatory diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of cendakimab compared with placebo in patients with moderate to severe AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging clinical trial was conducted from May 2021 to November 2022. Adult patients with moderate to severe AD and inadequate response to topical medications were enrolled at 69 sites in 5 countries (US [n\u2009=\u200926], Japan [n\u2009=\u200917], Canada [n\u2009=\u20099], Poland [n\u2009=\u20099], and Czech Republic [n\u2009=\u20098]). Data were analyzed between April 25, 2023, and October 16, 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Patients were randomized (1:1:1:1) to receive subcutaneous cendakimab, 360 mg, every 2 weeks; 720 mg, every 2 weeks; 720 mg, once weekly; or placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcome and Measure<\/jats:title><jats:p>Mean percentage change in Eczema Area and Severity Index scores from baseline to week 16. Hierarchical testing with multiplicity adjustment was performed for 720 mg, once weekly vs placebo, then 720 mg, every 2 weeks vs placebo, and then 360 mg, every 2 weeks vs placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 221 patients were randomized, and 220 received study drug (95 women [43%]; mean [SD] age, 37.7 [13.9] years; 720 mg, once weekly [54 (24%)]; 720 mg, every 2 weeks [55 (25%)]; 360 mg, every 2 weeks [55 (25%)]; placebo [56 (26%)]). The primary efficacy end point was met for cendakimab, 720 mg, once weekly vs placebo (\u201384.4 vs \u201362.7; <jats:italic>P<\/jats:italic>\u2009=\u2009.003) but missed statistical significance for 720 mg, every 2 weeks (\u201376.0 vs \u201362.7; <jats:italic>P<\/jats:italic>\u2009=\u2009.06). The treatment effect for 360 mg, every 2 weeks (\u221216.3; nominal <jats:italic>P<\/jats:italic>\u2009=\u2009.03 vs placebo) was comparable with 720 mg, once weekly (\u221221.8); however, significance was not claimed because the hierarchical testing sequence was interrupted. Of patients with treatment-emergent adverse events leading to discontinuation, 4 (7.4%) received 720 mg, once weekly; 2 (3.6%) 720 mg, every 2 weeks; 1 (1.8%) 360 mg, every 2 weeks; and 2 (3.6%) placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The results of this randomized clinical trial indicated that cendakimab was effective, generally safe, and well-tolerated in patients with moderate to severe AD. The primary end point was met with a significant reduction in Eczema Area and Severity Index scores with 720 mg, once weekly at week 16. Cendakimab demonstrated progressive AD improvement at all doses during 16 weeks of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04800315\">NCT04800315<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.2131","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T15:00:46Z","timestamp":1721228446000},"page":"856","source":"Crossref","is-referenced-by-count":19,"title":["Cendakimab in Patients With Moderate to Severe Atopic Dermatitis"],"prefix":"10.1001","volume":"160","author":[{"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[{"name":"Oregon Medical Research Center, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine, Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saakshi","family":"Khattri","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine, Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Schlessinger","sequence":"additional","affiliation":[{"name":"Skin Specialists P.C., Omaha, Nebraska"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Fukuoka University Faculty of Medicine, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[{"name":"Teikyo University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marni","family":"Wiseman","sequence":"additional","affiliation":[{"name":"University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartlomiej","family":"Kwiek","sequence":"additional","affiliation":[{"name":"Klinika Ambroziak Dermatologia, Lazarski University, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Machkova","sequence":"additional","affiliation":[{"name":"CCR Czech Prague, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misti","family":"Linaberry","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Zhang","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Franchin","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar D.","family":"Charles","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia H.M.C.","family":"De Oliveira","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"doi240023r1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.clindermatol.2018.05.007","article-title":"Epidemiology of adult atopic dermatitis.","volume":"36","author":"Sacotte","year":"2018","journal-title":"Clin Dermatol"},{"issue":"2","key":"doi240023r2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaad.2017.04.019","article-title":"Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey.","volume":"77","author":"Eckert","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi240023r3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/jid.2014.325","article-title":"Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study.","volume":"135","author":"Silverberg","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi240023r4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/DER.0000000000000161","article-title":"Burden of sleep and fatigue in US adults with atopic dermatitis.","volume":"27","author":"Yu","year":"2016","journal-title":"Dermatitis"},{"issue":"5","key":"doi240023r5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.amjoto.2010.07.013","article-title":"Chronic rhinosinusitis in the setting of other chronic inflammatory diseases.","volume":"32","author":"Chandra","year":"2011","journal-title":"Am J Otolaryngol"},{"issue":"2","key":"doi240023r6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.aller.2012.03.001","article-title":"The International Study of Asthma and Allergies in Childhood (ISAAC) -hase three: a global synthesis.","volume":"41","author":"Mallol","year":"2013","journal-title":"Allergol Immunopathol (Madr)"},{"key":"doi240023r7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3389\/fped.2019.00467","article-title":"Transcriptomic analysis links eosinophilic esophagitis and atopic dermatitis.","volume":"7","author":"Doucet-Ladev\u00e8ze","year":"2019","journal-title":"Front Pediatr"},{"issue":"3","key":"doi240023r8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE\u2013 and Institute of Medicine\u2013based recommendations.","volume":"132","author":"Chu","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"doi240023r9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/2040622318773686","article-title":"Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy.","volume":"9","author":"Ari\u00ebns","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"doi240023r10","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2147\/CCID.S267217","article-title":"Therapeutic potential of tralokinumab in the treatment of atopic dermatitis: a review on the emerging clinical data.","volume":"15","author":"Kelly","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"doi240023r11","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring.","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"doi240023r12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.alit.2020.01.005","article-title":"Implications of IL-13Ra2 in atopic skin inflammation.","volume":"69","author":"Furue","year":"2020","journal-title":"Allergol Int"},{"issue":"7","key":"doi240023r13","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13\u2013dominant disease with greater molecular heterogeneity compared to psoriasis.","volume":"139","author":"Tsoi","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"13","key":"doi240023r14","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.3390\/ijms20133324","article-title":"Scratching counteracts IL-13 signaling by upregulating the decoy receptor IL-13Ra2 in keratinocytes.","volume":"20","author":"Ulzii","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"doi240023r17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/105294199277860","article-title":"The International Conference on Harmonization good clinical practice guideline.","volume":"6","author":"Dixon","year":"1998","journal-title":"Qual Assur"},{"issue":"3","key":"doi240023r18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","article-title":"The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.","volume":"83","author":"Simpson","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi240023r19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.v181.4","article-title":"Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi240023r20","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.2018.178.issue-5","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9).","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"issue":"24","key":"doi240023r21","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"10013","key":"doi240023r22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"doi240023r23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/JXX.0000000000000088","article-title":"Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: a pooled analysis of two phase 2 clinical trials.","volume":"30","author":"Tofte","year":"2018","journal-title":"J Am Assoc Nurse Pract"},{"issue":"3","key":"doi240023r24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjd.v186.3","article-title":"Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials.","volume":"186","author":"Wollenberg","year":"2022","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi240023r25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.v184.3","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi240023r26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial.","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi240023r27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial.","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi240023r28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.v75.1","article-title":"Interleukin-13: targeting an underestimated cytokine in atopic dermatitis.","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"doi240023r29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"doi240023r30","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3390\/pharmaceutics15020568","article-title":"Targeting interleukin 13 for the treatment of atopic dermatitis.","volume":"15","author":"Lytvyn","year":"2023","journal-title":"Pharmaceutics"},{"key":"doi240023r31","doi-asserted-by":"publisher","DOI":"10.7573\/17404398","article-title":"Conjunctivitis in patients with atopic dermatitis treated with dupilumab.","volume":"9","author":"Ferreira","year":"2020","journal-title":"Drugs Context"},{"issue":"3","key":"doi240023r32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.v181.3","article-title":"Conjunctivitis in dupilumab clinical trials.","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi240023r33","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/bjd.2018.178.issue-5","article-title":"Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?","volume":"178","author":"Thyssen","year":"2018","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi240023r34","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/bjd.2019.180.issue-5","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis.","volume":"180","author":"Bakker","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi240023r35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jaad.2020.11.037","article-title":"Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: a systematic review and meta-analysis.","volume":"85","author":"Ravn","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi240023r36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial.","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"issue":"26","key":"doi240023r37","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma.","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"doi240023r38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis.","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"doi240023r39","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/jdv.v34.6","article-title":"Placebo response in phase 2 and 3 trials of systemic and biological therapies for atopic dermatitis-a systematic review and meta-analysis.","volume":"34","author":"Andreasen","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi240023r40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2019.05.102","article-title":"Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: a systematic review and meta-analysis.","volume":"82","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"doi240023r41","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/exd.2019.28.issue-7","article-title":"Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches.","volume":"28","author":"Moyle","year":"2019","journal-title":"Exp Dermatol"},{"issue":"4","key":"doi240023r42","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study.","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"doi240023r15","unstructured":"Bristol-Myers Squibb. Bristol-Myers Squibb to acquire Celgene to create a premier innovative biopharma co. Accessed March 1, 2024. https:\/\/news.bms.com\/news\/details\/2019\/Bristol-Myers-Squibb-to-Acquire-Celgene-to-Create-a-Premier-Innovative-Biopharma-Company\/default.aspx"},{"key":"doi240023r16","unstructured":"World Medical Association. WMA Declaration of Helsinki\u2014ethical principles for medical research involving human subjects. Accessed March 6, 2024. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2821285\/jamadermatology_blauvelt_2024_oi_240023_1723648269.8092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T22:42:55Z","timestamp":1724280175000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2821285"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.2131","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}